Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 5/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1838147 | 0.85 | MAPT (0.41) | GPR132LPAR1CTSKCTSLCTSB | |
| SCHEMBL1838049 | 0.80 | GPR132 (0.46) | GPR132LPAR1CTSKCTSLCTSB | |
| SCHEMBL1841619 | 0.77 | GPR132 (0.64) | GPR132CTSKHDAC1HDAC6ALDH1A1 | |
| SCHEMBL1836676 | 0.77 | CTSK (0.61) | GPR132CTSKCTSLCTSBCTSS | |
| SCHEMBL8504286 | 0.77 | HDAC6 (0.49) | GPR132LPAR1CTSKCTSLCTSB | |
| SCHEMBL1838927 | 0.76 | GPR132 (0.50) | GPR132CTSKCTSLCTSBCTSS | |
| SCHEMBL1837320 | 0.76 | CNR2 (0.49) | LPAR1CTSKCTSLCTSBCTSS | |
| SCHEMBL1813782 | 0.75 | CTSL (0.64) | CTSKCTSLCTSBCTSSHDAC1 | |
| SCHEMBL5105059 | 0.74 | FABP4 (0.51) | CTSKCTSLCTSBCTSSTSHR | |
| SCHEMBL1841973 | 0.72 | CNR2 (0.52) | LPAR1CTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8785631-B2 | Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core | SEIKAGAKU CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785631-B2 | Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core | SEIKAGAKU CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785631-B2 | Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core | SEIKAGAKU CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| CN-101370773-B | Cycloalkanecarboxamide derivative and method for producing same | SEIKAGAKU KOGYO CO LTD | 2014-04-09 | — | — | CN | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2036920-A1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2009-03-18 | — | — | EP | disclosed |
| CN-101370773-A | Cycloalkanecarboxamide derivative and method for producing same | SEIKAGAKU KOGYO CO LTD (JP) | 2009-02-18 | — | — | CN | disclosed |
| EP-1975162-A1 | OXAZOLONE DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2008-10-01 | — | — | EP | disclosed |
| EP-1972636-A1 | CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
| EP-1972615-A1 | CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131661-A1 | Oxazolone Derivatives | CTSK, CTSZ, CTSV | GPR132 1412/4885LPAR1 3040/4885CTSK 1/4885 |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | CTSK, CTSS, CTSV | GPR132 1193/4885LPAR1 1779/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.